Clinical trial
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With…
NCT00293475 · OHSU Knight Cancer Institute, Other · Unknown status
Key facts
| NCT number | NCT00293475 |
|---|---|
| Title | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma |
| Official title | A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Oregon Health and Science University |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Central Nervous System Lymphoma |
| Intervention type | Biological, Drug, Other |
| Interventions | Carboplatin, Mannitol, Methotrexate, Quality-of-Life Assessment, Rituximab, Sodium Thiosulfate |
| Enrollment | 81 |
| Start date | Oct 14, 2005 |
| Primary completion | Jan 31, 2022 |
| Completion | Jan 31, 2023 |
| First posted | Feb 17, 2006 |
| Last update posted | Sep 22, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: